Ultragenyx Pharmaceutical (RARE) News Today $38.98 +0.91 (+2.39%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period BlackRock, Inc. Reduces Stake in Ultragenyx Pharmaceutical Inc.April 30 at 9:05 PM | gurufocus.comUltragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate UpdateApril 30 at 5:00 PM | globenewswire.comFirst Light Asset Management LLC Has $32.13 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)First Light Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 763,607 shares of the bioApril 30 at 8:13 AM | marketbeat.comAquatic Capital Management LLC Purchases 78,571 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Aquatic Capital Management LLC lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 327.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 102,571 shares of the biopharmaceutiApril 30 at 6:31 AM | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Price T Rowe Associates Inc. MD cut its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,512,423 shares of the biopharmaceutical company's stock aApril 30 at 5:10 AM | marketbeat.comUltragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on ThursdayApril 30 at 3:59 AM | americanbankingnews.comRARE Ultragenyx Pharmaceutical Inc.April 29 at 11:29 AM | seekingalpha.com10,916 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Dark Forest Capital Management LPDark Forest Capital Management LP acquired a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,916April 29 at 5:07 AM | marketbeat.comTower Research Capital LLC TRC Buys 15,974 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Tower Research Capital LLC TRC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1,872.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 16,827 shares of the biopharmaceutical company's stock after purchasing anApril 29 at 4:37 AM | marketbeat.comBirchview Capital LP Invests $673,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Birchview Capital LP bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 16,000 shares of the biopharmaceutical company's stock, valued at approximately $673,000. UltragenyxApril 28 at 6:53 AM | marketbeat.com7,362 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Purchased by Syon Capital LLCSyon Capital LLC purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,362 shares of the biopharmaceutical company's stock,April 28 at 5:36 AM | marketbeat.comFirst Trust Advisors LP Raises Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)First Trust Advisors LP boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3,097.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,202 shares of the biopharmaApril 28 at 4:27 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. lowered its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 22.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,183,081 shares of theApril 27 at 5:59 AM | marketbeat.comBlue Owl Capital Holdings LP Sells 45,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Blue Owl Capital Holdings LP lowered its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 118,238 shares of the biopharmaceutical company's stock after selling 45,000 shApril 26, 2025 | marketbeat.comBarclays PLC Acquires 126,562 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Barclays PLC lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 159.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 206,108 shares of the biopharmaceutical company'sApril 26, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE) to Release Earnings on ThursdayUltragenyx Pharmaceutical (NASDAQ:RARE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-ultragenyx-pharmaceutical-inc-stock/)April 26, 2025 | marketbeat.comSilverarc Capital Management LLC Buys Shares of 124,388 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Silverarc Capital Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 124,388 shares of the biopharmaceutical company's sApril 24, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Rock Springs Capital Management LP's 9th Largest PositionRock Springs Capital Management LP cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,739,813 shares of the biopApril 23, 2025 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 22, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $92.79 Average Target Price from BrokeragesApril 22, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from AnalystsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and thirteen havApril 21, 2025 | marketbeat.comUltragenyx price target lowered to $80 from $83 at BofAApril 20, 2025 | markets.businessinsider.comWedbush Issues Pessimistic Forecast for RARE EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at Wedbush decreased their Q1 2025 EPS estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biopharmaceutical companyApril 20, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Marshall Wace LLPMarshall Wace LLP boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,051,573 shares of the biophApril 20, 2025 | marketbeat.comRussell Investments Group Ltd. Reduces Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Russell Investments Group Ltd. lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 21.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 69,187 shares of the biopharmaceutical company's stock after selling 19,424April 20, 2025 | marketbeat.comWedbush Issues Negative Estimate for RARE EarningsApril 20, 2025 | americanbankingnews.comResearch Analysts Set Expectations for RARE FY2027 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at Wedbush lowered their FY2027 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biopharmacApril 19, 2025 | marketbeat.comJump Financial LLC Purchases 87,825 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Jump Financial LLC lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 351.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 112,816 shares of the biopharmaceutical company's stock after acquiring an additional 87,April 19, 2025 | marketbeat.comRenaissance Technologies LLC Buys 72,600 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Renaissance Technologies LLC boosted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 39.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 254,700 shares of the biophApril 19, 2025 | marketbeat.comHow did Emil Kakkis build Ultragenyx into an ultra-rare disease powerhouse?April 17, 2025 | bizjournals.comUltragenyx: Commercial Engine Fuels Rare Disease PipelineApril 16, 2025 | seekingalpha.comInvesco Ltd. Grows Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Invesco Ltd. grew its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,699,756 shares of the biopharmaceutical company's stock aApril 16, 2025 | marketbeat.comGranite Investment Partners LLC Cuts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Granite Investment Partners LLC lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 160,415 shares of the biopharmaceutical coApril 15, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,562,790 shares of the bioApril 15, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 14, 2025 | msn.comF M Investments LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)F M Investments LLC purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 42,004 shares of the biopharmaceutical company's stock,April 14, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 52-Week Low - Should You Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Invests $337,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)ADAR1 Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 8,000 shares of the biopharmaceutical company's stock, valued at approxiApril 9, 2025 | marketbeat.comFederated Hermes Inc. Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Federated Hermes Inc. cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,049,800 shares of the biopharmaceutical company's stock afterApril 9, 2025 | marketbeat.comFranklin Resources Inc. Purchases 208,456 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Franklin Resources Inc. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 95.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 427,359 shares of the biopharmaceutical company's stockApril 9, 2025 | marketbeat.comCalifornia Public Employees Retirement System Purchases 17,225 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)California Public Employees Retirement System increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 131,344 shares of the biApril 9, 2025 | marketbeat.comExodusPoint Capital Management LP Purchases Shares of 87,017 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)ExodusPoint Capital Management LP acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 87,017 shares of the biopharmaceutical company's stock, valued at approximaApril 8, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Trims Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Massachusetts Financial Services Co. MA cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 500,717 shares of the biophaApril 8, 2025 | marketbeat.comBryce Point Capital LLC Invests $451,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Bryce Point Capital LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,719 shares of the biopharmaceutical company's stock, valued at approximately $451,000April 7, 2025 | marketbeat.comTrexquant Investment LP Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Trexquant Investment LP cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 156,656 shares of the biopharmaceutical company's stockApril 7, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stake Lessened by B. Metzler seel. Sohn & Co. AGB. Metzler seel. Sohn & Co. AG decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 35.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor oApril 7, 2025 | marketbeat.com961,794 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Norges BankNorges Bank bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 961,794 shares of the biopharmaceutical company's stock, valued at approximatelyApril 7, 2025 | marketbeat.comMotley Fool Asset Management LLC Has $2.04 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Motley Fool Asset Management LLC reduced its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 65.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,448 shares of the biopharmaceutical company's stocApril 6, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Raymond James Financial Inc. bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 21,774 shares of the biopharmaceutical company's stock, valued at approxApril 6, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)April 5, 2025 | markets.businessinsider.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.270.85▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼187▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Roivant Sciences News Revolution Medicines News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RARE Stock Free RARE Stock Alerts